Health ❯ Pharmaceuticals

Weight Loss

GLP-1 Drugs Medications Semaglutide Clinical Trials GLP-1 Medications Drug Development GLP-1 Agonists Drugs Obesity Novo Nordisk Obesity Treatment Mounjaro Prescription Medications Compounded Drugs Ozempic Counterfeit Drugs Injectable Drugs Prescription Drugs Orforglipron Wegovy Obesity Treatments Drug Safety Illicit Drugs Drug Efficacy Consumer Health Injectables Anti-Obesity Drugs Retatrutide Weight Loss Drugs GLP-1 Obesity Medications Sibutramine Weight Loss Pills Tirzepatide Medication Childhood Obesity GLP-1 Analog Drugs Drug Pricing GLP-1 Treatments FDA Approvals GLP-1 Inhibitors GLP Inhibitors Addiction Treatment Diabetes Incretin Drugs Telehealth Eli Lilly Diabetes Treatments Counterfeit Medications Injectable Medications Regulation Demand Trends Generic Drugs Market Trends Patient Experience

Nvidia Reportedly Pauses Intel 18A Chip Tests, Knocking Intel Shares

The reported pause raises fresh questions about Intel's bid to win external AI chip orders.

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

Costco Adds $499 Ozempic and Wegovy Offer Across U.S. Pharmacies

Eli Lilly Chooses Houston for $6.5 Billion Plant to Produce APIs for Orforglipron and Other Drugs

Chinese Weight-Loss Drug Suppliers Pivot to Generics as U.S. Crackdown Ends Copycat Boom

Guidelines Tie Diet and Exercise to GLP-1 Drug Success as India Launches Treatments

Hims & Hers Plans Canadian Launch of Generic Semaglutide After Zava Acquisition

Novo Nordisk Launches Wegovy Weight-Loss Drug in India

Tufts Chemists Unveil Four-Receptor Obesity Drug to Challenge Bariatric Surgery

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves